Fondaparinux in the treatment of acute coronary syndromes: Evidence from OASIS 5 and 6

Expert Review of Cardiovascular Therapy

Volumn 7, Issue 3, 2009, Pages 241-249

  Karthikeyan, Ganesan ^a   Mehta, Shamir R ^a   Eikelboom, John W ^a  

^a HAMILTON GENERAL HOSPITAL   (Canada)

Author keywords

Acute coronary syndrome; Fondaparinux; Major bleeding; Myocardial infarction; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; STREPTOKINASE; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; POLYSACCHARIDE;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADJUVANT THERAPY; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CATHETER THROMBOSIS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART REINFARCTION; HUMAN; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; RECOMMENDED DRUG DOSE; RISK BENEFIT ANALYSIS; RISK REDUCTION; ST SEGMENT ELEVATION; VENOUS THROMBOEMBOLISM; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

ACUTE CORONARY SYNDROME; ANTICOAGULANTS; DOUBLE-BLIND METHOD; ENOXAPARIN; FACTOR XA; HEMORRHAGE; HUMANS; MIDDLE AGED; MYOCARDIAL INFARCTION; POLYSACCHARIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 66149163355     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.7.3.241     Document Type: Article

References (26)

1. Murphy SA, Gibson CM, Morrow DA et al. Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. Eur. Heart J. 28(17), 2077-2086 (2007).
2. Yusuf S, Mehta SR, Xie C et al. Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. JAMA 293(4), 427-435 (2005).
3. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 114(8), 774-782 (2006).
4. Rao SV, Jollis JG, Harrington RA et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 292(13), 1555-1562 (2004).
5. Samama MM, Gerotziafas GT. Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux). Thromb. Res. 109(1), 1-11 (2003).
6. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch. Intern. Med. 162(16), 1833-1840 (2002).
7. Buller HR, Davidson BL, Decousus H et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized Kial. Ann. Intern. Med. 140(11), 867-873 (2004).
8. Buller HR, Davidson BL, Decousus H et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N. Engl. J. Med. 349(18), 1695-1702 (2003).
9. Coussement PK, Bassand JP, Convens C et al. A synthetic Factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study. Eur. Heart J. 22(18), 1716-1724 (2001).
10. Mehta SR, Steg PG, Granger CB et al. Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial. Circulation 111(11), 1390-1397 (2005).
11. Simoons ML, Bobbink IW, Boland J et al. A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study. J. Am. Coll. Cardiol. 43(12), 2183-2190 (2004).
12. Yusuf S, Mehta SR, Chrolavicius S et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N. Engl. J. Med. 354(14), 1464-1476 (2006).
13. Yusuf S, Mehta SR, Chrolavicius S et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 295(13), 1519-1530 (2006).
14. Mehta SR, Yusuf S, Granger CB et al. Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic Factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes. Am. Heart J. 150(6), 1107 (2005).
15. Mehta SR, Granger CB, Eikelboom JW et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J. Am. Coll. Cardiol. 50(18), 1742-1751 (2007).
16. Eikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusuf S. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 355(9219), 1936-1942 (2000).
17. Peters RJ, Joyner C, Bassand JP et al. The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial. Eur. Heart J. 29(3), 324-331 (2008).
18. Mehta SR, Boden WE, Eikelboom JW et al. Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials. Circulation 118(20), 2038-2046 (2008).
19. Amman EM, McCabe CH, Gurfinkel EP et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the Thrombolysis In Myocardial Infarction (TIMI) 11B trial. Circulation 100(15), 1593-1601 (1999).
20. Cohen M, Demers C, Gurfinkel EP et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N. Engl. J. Med. 337(7), 447-452 (1997).
21. Hirsh J, O'Donnell M, Eikelboom JW. Beyond unfractionated heparin and warfarin: current and future advances. Circulation 116(5), 552-560 (2007).
22. Montalescot G, White HD, Gallo R et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N. Engl. J. Med. 355(10), 1006-1017 (2006).
23. Stone GW, White HD, Ohman EM et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet 369(9565), 907-919 (2007).
24. Stone GW, Witzenbichler B, Guagliumi G et al. Bivalirudin during primary PCI in acute myocardial infarction. N. Engl. J. Med. 358, 2218-2230 (2008).
25. Anderson JL, Adams CD, Amman EM et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 116(7), e148-e304 (2007).
26. Bassand JP, Hamm CW, Ardissino D et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur. Heart J. 28(13), 1598-1660 (2007).